European markets traded mixed on Tuesday, but sentiment improved after a sharp rebound in Bayer shares. The stock surged about 13% following signals from the U.S. administration supporting the company’s effort to curb Roundup-related lawsuits. The development eased concerns over Bayer’s long-running legal exposure and helped lift Germany’s DAX, where the company remains a major component.
Broader sector performance varied, with financials showing strength while healthcare and consumer stocks lagged. The STOXX 600 held slightly in positive territory as investors weighed the potential impact of reduced litigation risk for Bayer and its implications for European value stocks.
Market participants said the policy shift in the U.S. could materially alter Bayer’s risk profile heading into 2026. The move also reinforced expectations that regulatory clarity may improve valuations for companies with significant legal overhangs across Europe.